CD274 and non-small cell lung carcinoma: Since 2017, the practice-changing results of the PACIFIC trial demonstrated sustained survival benefit from consolidation anti-programmed death ligand-1 (PD-L1) durvalumab in unresectable stage III NSCLC, with the median progression-free survival (PFS) of 16.9 months and median overall survival (OS) of 47.5 months (5, 6).